Overall survival
Mean overall survival (OS) was 13.8 years (median was not reached) with 96% at 3 years, 93% at 5 years, 83% at 10 years and 64% at 15 years after RT. For low-grade meningioma survival rate was 97% at 3 years, 94% at 5 years, 85% at 10 years and 65% at 15 years, for atypical meningioma 91% at 3 years, 86% at 5 years, 62% at 10 years and 50% at 15 years. As expected OS is significantly better for low-grade meningioma (p=.034, Figure 1). Stratified by histology, we compared groups of gender, pre-surgery, time between prior surgery and RT, tumor volume and age. We found a significant better survival for a tumor volume < 50 years (p=.029) (Table 2). These factors remained significant also in the multivariate analysis.
One of the …show more content…
no)
.9
1.035
-
.7
.719
-
Time surgery until RT (< vs. >= 6 months)
.5
.662
-
.8
.896
-
Tumor volume (< vs. >= 35 ml)
.013 *
2.231
.015 *
.5
1.269
-
Tumor volume (not grouped)
.026 *
1.004
???
.001 *
1.004
.008 *
Age (< vs. >= 50 years)
.034 *
2.405
.037 *
.3
1.539
-
Age (not grouped)
=3 occurred. Most clinical symptoms were already apparent before therapy. Table 2 describes all new and worsened symptoms and toxicity during and after irradiation according to CTCAE classification. Most patients indicated an improvement of side effects or a constant state.
During RT typical side effects, such as hair loss (38.5%), hyperpigmentation (3.7%), skin erythema (22.6%) and fatigue (39.3%) occurred, which continuously improved. Of all, 3.0% of patients reported worsened and new symptoms grade >=3 during RT and the first six months after RT, and 17.5% after more than two years. Most high grade side-effects were visual deficits and hearing impairment. Eight cases with grade 4 toxicity occurred, of these two in hearing impairment. In both patients hearing impairment was present bevor RT and steadily progressed during follow-up. The remaining six grade 4 cases occurred as visual deficits. Two patients had already deficits before RT, which progressed during follow-up; in four patients severe visual deficits were contributed due to tumor progression > 2 years after
Mean overall survival (OS) was 13.8 years (median was not reached) with 96% at 3 years, 93% at 5 years, 83% at 10 years and 64% at 15 years after RT. For low-grade meningioma survival rate was 97% at 3 years, 94% at 5 years, 85% at 10 years and 65% at 15 years, for atypical meningioma 91% at 3 years, 86% at 5 years, 62% at 10 years and 50% at 15 years. As expected OS is significantly better for low-grade meningioma (p=.034, Figure 1). Stratified by histology, we compared groups of gender, pre-surgery, time between prior surgery and RT, tumor volume and age. We found a significant better survival for a tumor volume < 50 years (p=.029) (Table 2). These factors remained significant also in the multivariate analysis.
One of the …show more content…
no)
.9
1.035
-
.7
.719
-
Time surgery until RT (< vs. >= 6 months)
.5
.662
-
.8
.896
-
Tumor volume (< vs. >= 35 ml)
.013 *
2.231
.015 *
.5
1.269
-
Tumor volume (not grouped)
.026 *
1.004
???
.001 *
1.004
.008 *
Age (< vs. >= 50 years)
.034 *
2.405
.037 *
.3
1.539
-
Age (not grouped)
=3 occurred. Most clinical symptoms were already apparent before therapy. Table 2 describes all new and worsened symptoms and toxicity during and after irradiation according to CTCAE classification. Most patients indicated an improvement of side effects or a constant state.
During RT typical side effects, such as hair loss (38.5%), hyperpigmentation (3.7%), skin erythema (22.6%) and fatigue (39.3%) occurred, which continuously improved. Of all, 3.0% of patients reported worsened and new symptoms grade >=3 during RT and the first six months after RT, and 17.5% after more than two years. Most high grade side-effects were visual deficits and hearing impairment. Eight cases with grade 4 toxicity occurred, of these two in hearing impairment. In both patients hearing impairment was present bevor RT and steadily progressed during follow-up. The remaining six grade 4 cases occurred as visual deficits. Two patients had already deficits before RT, which progressed during follow-up; in four patients severe visual deficits were contributed due to tumor progression > 2 years after